Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-18-018317
Filing Date
2018-06-27
Accepted
2018-06-27 16:24:54
Documents
1
Period of Report
2018-06-25

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5645
  Complete submission text file 0000899243-18-018317.txt   7030
Mailing Address 245 FIRST STREET 4TH FLOOR CAMBRIDGE MA 02142
Business Address 245 FIRST STREET 4TH FLOOR CAMBRIDGE MA 02142 857-201-2700
Magenta Therapeutics, Inc. (Issuer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O MAGENTA THERAPEUTICS 50 HAMPSHIRE STREET CAMBRIDGE MA 02139
Business Address
DAVIS JOHN C. JR (Reporting) CIK: 0001741287 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38541 | Film No.: 18922037